1. Home
  2. JYD vs IMRN Comparison

JYD vs IMRN Comparison

Compare JYD & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JYD

Jayud Global Logistics Limited

N/A

Current Price

$0.76

Market Cap

8.6M

ML Signal

N/A

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$1.27

Market Cap

9.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JYD
IMRN
Founded
2001
1994
Country
China
Australia
Employees
N/A
N/A
Industry
Oil Refining/Marketing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.6M
9.6M
IPO Year
2022
2016

Fundamental Metrics

Financial Performance
Metric
JYD
IMRN
Price
$0.76
$1.27
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
215.9K
44.2K
Earning Date
05-15-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.12
$0.68
52 Week High
$6.85
$2.38

Technical Indicators

Market Signals
Indicator
JYD
IMRN
Relative Strength Index (RSI) 35.47 59.55
Support Level $0.61 $0.72
Resistance Level $1.09 $1.60
Average True Range (ATR) 0.12 0.13
MACD 0.08 0.02
Stochastic Oscillator 17.69 73.23

Price Performance

Historical Comparison
JYD
IMRN

About JYD Jayud Global Logistics Limited

Jayud Global Logistics Ltd is an end-to-end supply chain solution provider in China, with a focus on providing cross-border logistics services. The company offers freight forwarding services, fragmented logistics, and chartered airline freight services, supply chain management, and other value-added services.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Share on Social Networks: